Leflunomid Egis

Leflunomide, the active ingredient in Leflunomid Egis, is an immunomodulator presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, acting as a disease‑modifying antirheumatic drug (DMARD) that helps reduce joint inflammation and slow structural damage.\n\nGNH India supplies Leflunomid Egis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug (DMARD) used to manage inflammatory arthritis conditions.\n\nRheumatoid arthritis: reduces joint inflammation, pain, and slows radiographic progression.\nPsoriatic arthritis: improves skin lesions and joint symptoms, helping maintain functional ability.

Leflunomide may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Diarrhea: mild to moderate gastrointestinal upset.\n- Nausea: occasional feeling of sickness.\n- Elevated liver enzymes: mild increases in hepatic laboratory values.\n- Hypertension: rise in blood pressure that may require monitoring.\n\nSerious or Rare Side Effects:\n- Severe liver injury: risk of hepatitis or hepatic failure.\n- Stevens‑Johnson syndrome: rare, life‑threatening skin reaction.\n- Bone marrow suppression: may cause anemia, leukopenia, or thrombocytopenia.

Before initiating therapy, clinicians should assess several safety considerations.\n\nPregnancy contraindication: teratogenic risk mandates avoidance in pregnant women.\nLiver function monitoring: baseline and periodic tests are required due to hepatotoxic potential.\nBlood count monitoring: regular CBCs to detect bone‑marrow suppression.\nInfection risk: patients should be evaluated for active infections before treatment.\nConcomitant warfarin use: may increase anticoagulant effect and require INR monitoring.\nStore at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Leflunomide can interact with several medicines, influencing efficacy or safety.\n\nMajor Interactions (Avoid):\n- Warfarin: may potentiate anticoagulant effect, increasing bleeding risk.\n- Statins (e.g., simvastatin): heightened risk of myopathy and rhabdomyolysis.\n- Live vaccines: immunosuppression can lead to severe infection from vaccine strains.\n\nModerate Interactions (Monitor Closely):\n- Methotrexate: additive hepatotoxicity warrants liver function surveillance.\n- Carbamazepine: induces metabolism, potentially lowering leflunomide plasma levels.